Bonow RO, Yancy CW: High-intensity statins for secondary prevention. JAMA Cardiol 2017;2:55.
Cannon CP et al: Ezetimibe added to statin therapy after acute coronary syndrome. N Engl J Med 2015;372:2387.
Chou R et al: Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008.
Dron JS, Hegele RA: Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol 2017;28:161.
Elam M, Lovato E, Ginsberg H: The role of fibrates in cardiovascular disease prevention, The ACCORD–lipid perspective. Curr Opin Lipidol 2011;22:55.
Gaudet D et al: Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015;373:438.
Gouni-Berthold I et al: Systematic review of published phase 3 data on antiPCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 2016;82:1412.
International Atherosclerosis Society: IAS Position Paper: Global Recommendations for the Management of Dyslipidemia. Available at: www.athero.org/ IASPositionPaper.asp.
Jacobson TA et al: On behalf of the NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol 2015;9:S1.
LaRosa JC et al: Safety and effect of very low levels of low density lipoprotein cholesterol on cardiovascular events. Am J Cardiol 2013;111:1221.
Mampuya WM et al: Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 2013;166:597.
Nduka C et al: Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol 2015;199:307.
Perry CM: Lomitapide: A review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 2013;13:265.
Raal FJ, Stein EA: The effects of mipomersen on inhibiting hepatic VLDL apolipoprotein B 100 and propensity for hepatic steatosis. Clin Chem 2016;62:1052.
Reith C, Armitage J: Management of residual risk after statin therapy. Atherosclerosis 2016;245;161.
Rodriguez F: Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2016;2:47.
Silverman MG et al: Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA Cardiol 2016;316:1289.